Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*

@article{Chapman2004RaisingHL,
  title={Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*},
  author={M. John Chapman and Gerd Assmann and J-C. Fruchart and James Shepherd and Cesare R. Sirtori},
  journal={Current Medical Research and Opinion},
  year={2004},
  volume={20},
  pages={1253 - 1268}
}
SUMMARY Reduction of low-density lipoprotein cholesterol (LDL-C) is presently the primary focus of lipid-lowering therapy for prevention and treatment of coronary heart disease (CHD). However, the high level of residual risk among statin-treated patients in recent coronary prevention studies indicates the need for modification of other major components of the atherogenic lipid profile. There is overwhelming evidence that a low plasma level of high-density lipoprotein cholesterol (HDL-C) is an… 
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus
TLDR
Therapeutic lifestyle changes and pharmacological intervention aimed at raising HDL-C, should benefit patients, and to achieve target LDL-C levels exercise are important interventions for raising cholesterol levels.
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
TLDR
In conclusion, this European Expert Panel recommends that combination therapy with a statin and an HDL-C raising agent, such as PR nicotinic acid, should be considered in patients, who remain at high residual risk despite achieving target LDL-C levels with statin monotherapy.
Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid
TLDR
The addition of nicotinic acid to primary statin therapy is a logical approach to dyslipidaemia management, and is supported by recent clinical trials such as the Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2 study.
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Several large statin trials and meta-analyses have demonstrated a reduction in low-density lipoprotein cholesterol (LDL-C) and cardiovascular morbidity and mortality. Some trials have also
High-density lipoprotein metabolism: potential therapeutic targets.
Reducing risk by raising HDL-cholesterol: the evidence
TLDR
The evidence base supporting intervention to correct low HDL-cholesterol in addition to reducing LDL-ch cholesterol is now sufficiently strong to support the introduction of this strategy into routine clinical practice.
Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
  • A. Wierzbicki
  • Biology, Medicine
    Current medical research and opinion
  • 2005
TLDR
The available clinical evidence suggests that addition of nicotinic acid to primary lipid-lowering therapy has an important atheroprotective role in patients with or at risk of developing CHD.
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
TLDR
The accumulating evidence suggesting that HDL possesses a diverse range of biological actions, and that increasing HDL levels by drug treatment may be beneficial in the prevention of cardiovascular disease, is discussed.
Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia
Observational cohort studies and analysis of the populations of intervention trials at baseline reveal a strong inverse association between circulating levels of high-density lipoprotein
When high is low: Raising low levels of high-density lipoprotein cholesterol
  • P. Toth
  • Biology, Medicine
    Current cardiology reports
  • 2008
TLDR
Currently available therapies to raise suboptimal levels of high-density lipoprotein cholesterol and to augment HDL functionality are discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 123 REFERENCES
Clinical usefulness of HDL cholesterol as a target to lower risk of coronary heart disease: Summary of evidence and recommendations of an expert group
TLDR
An international group of experts in epidemiology, clinical and basic science formed a consensus that an HDLc concentration of 1.0 mmol/L (40 mg/dL) is a realistic clinical guideline for patients at high risk of a coronary event, and specific diet and drug therapies were recommended.
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
TLDR
Patients with elevated HDL cholesterol, low HDL-C, and elevated triglycerides were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome, had increased risk for CHD events on placebo, and received greater benefit with simvastatin therapy.
GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
TLDR
Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study
TLDR
Optimal LDL-C values are <100 mg/dL in both women and men, and LDL- C, HDL-C, TG, and Lp(a), without additional apolipoproteins or lipid subfractions, provide substantial CHD prediction, with much higher RR in women than men.
A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression.
TLDR
It is suggested that HDL-mediated increases in eNOS expression may contribute to the observed enhancement in vasorelaxation and thus support a previously unrecognized mechanism for the beneficial cardiovascular effects of HDL.
...
1
2
3
4
5
...